ESR1 and breast carcinoma: Although TAM is widely used in the treatment of ERα-positive breast cancer patients, it has been reported that the use of AIs, e.g., anastrozole, letrozole and exemestane, as well as fulvestrant, offer better clinical outcomes by improving disease-free survival and reducing the risk of recurrence [10,35,219].